Eric Taylor Baumgartner, MD | |
75166 Woodland Rd, Abita Springs, LA 70420-2958 | |
(985) 892-3726 | |
Not Available |
Full Name | Eric Taylor Baumgartner |
---|---|
Gender | Male |
Speciality | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine |
Location | 75166 Woodland Rd, Abita Springs, Louisiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1588966519 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083P0500X | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine | MD 016156 (Louisiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Eric Taylor Baumgartner, MD Po Box 307, Abita Springs, LA 70420-0307 Ph: (504) 813-3688 | Eric Taylor Baumgartner, MD 75166 Woodland Rd, Abita Springs, LA 70420-2958 Ph: (985) 892-3726 |
News Archive
Health-conscious consumers are paying closer attention to the numbers and dates stamped on the bottom of their favorite cereals, canned goods, packaged snacks and even fresh produce. But what do all these numbers really mean?
National guidelines assume that all patients who're diagnosed with clinical sepsis in an emergency department will be admitted to the hospital for additional care, but new research has found that many more patients are being treated and released from the ED for outpatient follow-up than previously recognized.
World Children's Day marks the day, over three decades ago, on which world leaders adopted the historic Convention of the Rights of the Child, promising to every child to promote and protect their rights, including the right to life and the right to health.
"Gov. Arnold Schwarzenegger [of California] on Wednesday conceded that long-standing delays in disciplining errant health professionals were 'absolutely unacceptable' and promised broad reforms to better protect patients from dentists, pharmacists, therapists and others accused of misconduct," ProPublica/The Los Angeles Times reports.
Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) announced that health authorities are reviewing scientific data from two clinical trials evaluating an investigational use of the company's Alzheimer's treatment, Reminyl (galantamine hydrobromide), in individuals with mild cognitive impairment.
› Verified 2 days ago